首頁
Phasebio Pharmaceuticals, Inc.

11月 2025Phasebio Pharmaceuticals...的市場佔有率分析

The Investor Relations website contains information about PhaseBio Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

健康 > 生物技術和製藥

域名phasebio.com

成立年份2002

僱員51 - 200

年度營收$10M - $15M

Phasebio Pharmaceuticals, Inc.

Phasebio Pharmaceuticals, Inc.（包含公司地區）

phasebio.com

查看更多網站流量與參與度資訊

Phasebio Pharmaceuticals, Inc.截至 11月 2025 的總收入為 10M - 15M

Phasebio Pharmaceuticals, Inc. 熱門網域產生的總收入

Phasebio Pharmaceuticals, Inc. 熱門網域 3 年內的總收入

Phasebio Pharmaceuticals, Inc. 熱門網域的總收入

phasebio.com10M - 15M

透過銷售情報查看更多內容

Phasebio Pharmaceuticals, Inc.的熱門網域總造訪量

了解Phasebio Pharmaceuticals, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

phasebio.com706

透過銷售情報查看更多內容

Phasebio Pharmaceuticals, Inc.的熱門網域平均造訪時長

分析Phasebio Pharmaceuticals, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

phasebio.com00:00:53

透過銷售情報查看更多內容

Phasebio Pharmaceuticals, Inc.的熱門網域平均頁面瀏覽量

了解Phasebio Pharmaceuticals, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

phasebio.com2.16

透過銷售情報查看更多內容

Phasebio Pharmaceuticals, Inc.按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

clinipace.com公司名Clinipace僱員1001 - 5000總部美國, 北卡羅來納, Morrisville年度營收$200M - $500M訪問總量--健康 > 生物技術和製藥

使用的熱門技術Phasebio Pharmaceuticals, Inc.

这些是Phasebio Pharmaceuticals, Inc.顶级域名使用的行业网站技术

轉換與分析 (8)

Google Analytics

小工具 (6)

Twemoji

付費廣告 (3)

Google Adsense

內容管理系統 (3)

WordPress

更多技術

9

檢視所有

新聞與訊號來自Phasebio Pharmaceuticals, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Phasebio has issues with potential breach of fiduciary duty claim.Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS).

新聞Phasebio had issues with Chapter 11 bankruptcy on Oct 31st '22.PhaseBio plans to file Chapter 11 bankruptcy and sell off its bentracimab assets under a "stalking horse: arrangement with an unnamed large pharmaceutical company, the company announced Monday.

新聞Phasebio receives financing of $40M in Series C.The center will be located near the Research Triangle Park in Cary, North Carolina where the company will, according to Novozymes, invest $36 million over the next three years and… PhaseBio Pharmaceuticals, Inc. a biopolymer-based drug manufacturer, has raised $40 million in a Series C round of funding, which includes a major share from AstraZeneca.